Biogen Releases Q3 SMA Community Statement
Learn about Biogen’s latest news in SMA by viewing their Community Statement and a related video.
Biogen Releases Q3 SMA Community Statement Read More »
November 2022
The Giving Season is Here!
Cure SMA leads the way to a world where everyone impacted by SMA is empowered to lead their best lives. As 2022 comes to a close, we celebrate stories of breakthroughs powered by research and care, while also recognizing that our work is not done. This is Cure SMA’s commitment to our community. Key components
The Giving Season is Here! Read More »
Community Spotlight: Michelle Tynski and Family
Play is important for kids. It allows children to develop cognitive, social, emotional, and physical skills while engaging creatively. But it’s not just how kids play that’s important, what they play with also matters. Which is why Michelle Tynski, mom to nine-year-old Trace, Benjamin who passed away in 2016, and 3-year-old Zach, who has Type
Community Spotlight: Michelle Tynski and Family Read More »
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
Genentech, announced earlier this month new two-year data from the JEWELFISH study evaluating Evrysdi® (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at time of enrollment. Patients had been previously treated with other approved or investigational SMA-targeting therapies, including Spinraza® or Zolgensma®. Data showed Evrysdi improved or maintained motor function